CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Pasireotide diaspartate

Last Updated: February 27, 2014
Result type: Reports
Project Number: SR0372-000
Product Line: Reimbursement Review

Generic Name: Pasireotide diaspartate

Brand Name: Signifor

Manufacturer: Novartis Pharmaceuticals Inc.

Therapeutic Area: Cushing’s disease

Indications: Cushing’s Disease

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 24, 2015

Recommendation Type: Do not list